Supplementary Figure 3
Increased avidity and efficacy of dAbd over scFv C7 in 6647 EWS cell line.

(A) The two antibodies ScFv C7 and dAbd C7 were tested together in an ELISA assay at the same range of concentrations, on recombinant antigen CD99. dAbd C7 shows a greater avidity for antigen compared to ScFv C7. (B) Increased apoptotic effect of dAbd C7 compared scFv C7. The two antibodies were tested at the concentration of 200μg/ml for 3 or 6 hours of treatment.